Under the terms of the collaboration, the selection of the compound triggers a milestone payment to Pharmacopeia. “Schering-Plough’s advancement of this compound further expands our already significant development-stage
By expanding the trial, Emisphere will be able to evaluate the performance of all three active arms of the trial against each other for statistical significance. Without the
The single-agent, open-label phase I study of CHIR-265 is designed to evaluate the safety, dose tolerability and pharmacokinetic profile of CHIR-265 in patients with melanoma – a type
According to the Association of the British Pharmaceutical Industry (ABPI), medicines earned a trade surplus for the UK of GBP3.4 billion in 2005, a drop of 8% on
Speaking at a celebration to mark the delivery of the three millionth vaccine dose, New Zealand minister of health Pete Hodgson said that new data confirms that the
The consumer group, Public Citizen, said that the obesity treatment can cause a significant increase in aberrant crypt foci (ACF) – widely believed to be a precursor to
The drug, which is already approved as a treatment for a type of leukemia and for a type of stomach and intestine cancer, has now been submitted for
Their ‘cargo carrier’ peptide, named pHLIP, accumulates in the membranes of cells in acidic environments and spontaneously transfers attached molecules across the membrane. The cargo is then released
Sanofi-Aventis is contesting the case with drugmakers Teva and Amphastar, which want to produce and sell cheaper generic versions of the drug. Although the decision of the appeals
Fabry disease is a lysosomal storage disorder caused by an enzyme deficiency that leads to pain, kidney failure, and an increased risk of heart attack and stroke. Amigal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.